INTERVIEW: Ex-Advinus CEO’s Bittersweet Journey

Life appears to have come full circle for Advinus Therapeutics' co-founder and former CEO and managing director, Dr. Rashmi Barbhaiya, who recently moved back to the US from India. It has been a bitter-sweet journey with peaks and troughs, although the man himself would rather see any lows as "lessons learned" that come with the territory.

"It is with mixed feelings I have returned to US after relentless pursuit of 14 years. I do want to keep the reins of my destiny in my hand," declares Dr. Rashmi Barbhaiya, who began his industrial pharmaceutical career in 1980 with Bristol-Myers Squibb Co. in the US and is a co-founder and ex-CEO of India’s Advinus Therapeutics Pvt. Ltd.

In an interview with PharmAsia News’s sister publication Scrip, he also lamented the limited understanding of investors in India of pharma R&D, but more on that later.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

03 Jun 2025

• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

MetaVia Sees Obesity Opportunities Despite Challenging US Market

03 Jun 2025

• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

Public Health And Innovation: Addressing Gaps, Pharma’s Role

02 Jun 2025

• By Anju Ghangurde

Expert panel including Ashok Venkitaraman, director of the Cancer Science Institute of Singapore, discusses public health challenges and innovations to help address these. Long-acting drugs, intercepting cancer early and “design thinking” by ophthalmologists in India were among the talking points.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

03 Jun 2025

• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.